Does Blue Cross Blue Shield Cover Saxenda?

Print or save as PDF

Key numbers

  • 3 mgStandard daily Saxenda (liraglutide) dose, injected under the skin once a daySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 0.6 mgStarting daily Saxenda dose, taken for the first week before weekly increasesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 16 weeksPoint after starting when adults' weight change is checked under the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 4%Minimum weight loss by adults at 16 weeks; less than this and the label says to stop SaxendaSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Liraglutide

At a glance

  • Drug / Saxenda (liraglutide) 3 mg once-daily injection [1]
  • Approved use / Weight management with diet and activity [1]
  • Who it is for / Adults with obesity, or overweight plus a weight-related condition; ages 12+ above 60 kg with obesity [1]
  • Generic option / FDA-approved generic liraglutide labels referencing Saxenda exist [2]
  • Combination limit / Label says not recommended with another liraglutide product or any other GLP-1 receptor agonist [1]

What the Saxenda label covers

Saxenda is liraglutide 3 mg, a GLP-1 receptor agonist injected once daily under the skin of the abdomen, thigh, or upper arm, at any time of day and without regard to meals [1]. The labeled use is weight management alongside a reduced-calorie diet and more physical activity in the groups described above [1]. Plans that cover it may tie coverage to these labeled uses, but that is a plan decision.

Questions worth asking

Choose the questions you want to keep

The 16-week checkpoint in the label

Dosing starts at 0.6 mg daily for one week, then rises weekly to 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg daily from week 5 [1]. For adults, the label says to evaluate weight change 16 weeks after starting and to discontinue Saxenda if less than 4% of baseline body weight has been lost [1].

Generic liraglutide and compounded products

FDA-approved generic liraglutide labels that reference Saxenda exist, for example from Teva, Biocon, and Cipla [2]. Compounded drugs are not FDA approved and are not reviewed by FDA for safety, effectiveness, or quality before they are marketed [3]. On 2026-04-30, FDA proposed excluding liraglutide, semaglutide, and tirzepatide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need. Comments were due by 2026-06-29, and a final decision was not found [4].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, where is Saxenda injected?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Frequently asked questions

Does Blue Cross Blue Shield cover Saxenda?
It varies by individual BCBS plan, and no single national BCBS policy for Saxenda is documented on this page. Saxenda itself is FDA-approved for weight management in the groups described in the label [1].
What does the label say about the 16-week weight check?
For adults, the label says to evaluate weight change 16 weeks after starting and to discontinue Saxenda if less than 4% of baseline body weight has been lost [1].
What does the label say about combining Saxenda with other GLP-1 drugs?
The Saxenda label says coadministration with other liraglutide-containing products or any other GLP-1 receptor agonist is not recommended [1].

References

Show all 4 referencesHide references
Does blue cross blue shield cover saxenda: evidence summary chart
Image: HealthRX.com. Full does blue cross blue shield cover saxenda guide and sources at healthrx.com/glp-1-faq.